Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Rutgers, The State University of New Jersey
Sponsor:
Collaborators:
Rutgers Cancer Institute of New Jersey
Information provided by (Responsible Party):
Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:
NCT01649947
First received: July 20, 2012
Last updated: May 15, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to examine the combination of one standard treatment for lung cancer plus an additional drug, hydroxychloroquine. The standard treatment for lung cancer being used includes 2 chemotherapy drugs, called paclitaxel and carboplatin. Some patients who have a specific type of lung cancer can also receive another drug, a drug that targets blood vessels, called bevacizumab (also known as avastin). Hydroxychloroquine is an FDA approved drug for the treatment of malaria, rheumatoid arthritis and lupus erythematosis.


Condition Intervention Phase
Non-small Cell Lung Cancer
Advanced Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Drug: Paclitaxel
Drug: Carboplatin
Drug: Hydroxychloroquine
Drug: Bevacizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)

Resource links provided by NLM:


Further study details as provided by Rutgers, The State University of New Jersey:

Primary Outcome Measures:
  • Antitumor activity, as measured by tumor response rate of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer [ Time Frame: 6 years ] [ Designated as safety issue: No ]
    Assessed using RECIST criteria. Determined using a Simon's two-stage minimax design with a 5% significance level and 80% power.


Secondary Outcome Measures:
  • Time to progression [ Time Frame: 8 years ] [ Designated as safety issue: No ]
    Kaplan-Meier estimates of survival function and the standard errors will be calculated. The median survival times and 95% confidence intervals will be presented.

  • Survival [ Time Frame: 8 years ] [ Designated as safety issue: No ]
    Estimated with the presentation of its 95% confidence interval.

  • Overall survival [ Time Frame: 8 years ] [ Designated as safety issue: No ]
    Kaplan-Meier estimates of survival function and the standard errors will be calculated. The median survival times and 95% confidence intervals will be presented.

  • Toxicity of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer [ Time Frame: 8 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: December 2011
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 2: Bevacizumab ineligible patients
Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Hydroxychloroquine 200 mg PO BID
Drug: Paclitaxel

Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.

Prior to receiving paclitaxel, all patients will receive the following premedication:

  • Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv < 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)
  • Diphenydramine 50 mg iv (or equivalent) < 1 hour prior to paclitaxel infusion
  • Ranitidine 50 mg iv < 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)
Other Name: Taxol
Drug: Carboplatin
Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
Other Name: Paraplatin
Drug: Hydroxychloroquine
Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
Other Name: Plaquenil
Experimental: Cohort 1: Bevacizumab eligible patients
Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for Hydroxychloroquine 200 mg PO BID
Drug: Paclitaxel

Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.

Prior to receiving paclitaxel, all patients will receive the following premedication:

  • Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv < 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)
  • Diphenydramine 50 mg iv (or equivalent) < 1 hour prior to paclitaxel infusion
  • Ranitidine 50 mg iv < 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)
Other Name: Taxol
Drug: Carboplatin
Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
Other Name: Paraplatin
Drug: Hydroxychloroquine
Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
Other Name: Plaquenil
Drug: Bevacizumab

Cohort 1 only:

Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles.

Other Name: Avastin

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed a protocol-specific informed consent.
  • 18 years of age or older.
  • ECOG Performance Status 0 or 1.

Cancer criteria:

  • Histologically or cytologically confirmed non-small cell lung cancer. Mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible. Cytologic or histologic elements can be established on metastatic tumor aspirate or biopsy. Sputum cytology alone is not sufficient.
  • Advanced stage NSCLC (stage IVa ((malignant pleural effusion (is now staged as stage IVa by the most recent staging system), or stage IV, or recurrent disease)).
  • Measurable disease according to RECIST criteria.
  • Patient with CNS metastasis are required to have stable disease documented by being off treatment (surgery, radiation therapy) for at least 2 weeks, and four (4) weeks is preferred. A contrast enhanced brain CT or brain MRI is required within 35 days of enrollment. Patients with brain metastases who qualify for protocol therapy will be included in Cohort 2 (ineligible for treatment with Bevacizumab).
  • Prior radiation to sites other than the brain is allowed, if completed at least 2 weeks before treatment and provided that all radiation-related toxicities have resolved to ≤ Grade 1.

Laboratory requirements

- Adequate organ function, as evidenced by ALL the following:

  • absolute neutrophil count (ANC) ≥ 1500/mm³
  • platelet count ≥ 100,000/mm³
  • hemoglobin ≥ 9 gm/dL
  • total bilirubin ≤ 1.5 x ULN; if patient has Gilbert's disease, then patient must have isolated hyperbilirubinemia (e.g. no other liver function test abnormality), with maximum bilirubin ≤ 2 X institutional ULN.
  • AST and ALT ≤ 2.5 x ULN in the absence of liver metastases; AST and ALT ≤ 5 x ULN in the presence of liver metastases
  • alkaline phosphatase ≤ 2.5 x ULN
  • creatinine ≤ 1.5 X institutional ULN or calculated creatinine clearance ≥ 60 ml/min as estimated using the Cockcroft-Gault formula.

Comorbidities For Cohort 1: (Bevacizumab eligible)

  • For patients who have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipate the need for such while on active treatment, may participate and receive Bevacizumab at the start of the second or third cycle as they would under standard care. Placement of vascular access device is not considered major surgery, but the incision must have healed before initiation of treatment.
  • Patients must have a systolic blood pressure ≤ 150 mm Hg and diastolic blood pressure ≤ 100 mm Hg (the use of antihypertensive medications to achieve these goals is allowed).
  • Adequate organ function

    • INR ≤ 1.5 and aPTT WNL.
    • Urine Protein Creatinine (UPC) ratio < 1.0 or 24 hour urine protein ratio < 1000 mg

UPC ratio of spot urine is an estimation of the 24 urine protein excretion. A UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm. To obtain a UPC ratio:

  • Obtain at least 4 mL of a random urine sample
  • Determine protein and creatinine concentration
  • Calculate the UPC using one of the following formulae [urine protein]/[urine creatinine] - if both values are reported in mg/dL [(urine protein) x 0.088]/[urine creatinine] - if urine creatinine is reported in mmol/L

For ALL (Cohort 1 and Cohort 2):

  • Women must:

    • Have a negative serum or urine pregnancy test within 7 days prior to study entry if she is a woman of child-bearing potential, OR
    • Be at least one year post-menopausal, OR
    • Be surgically sterile
  • Patients of childbearing or child fathering potential must be willing to use an acceptable method of birth control prior to study entry and for the duration of the study. Acceptable methods of contraception include hormonal, barrier methods, intrauterine device, tubal ligation/vasectomy or abstinence.

Exclusion Criteria:

Cancer criteria:

  • No prior cytotoxic chemotherapy or targeted therapy in the advanced or metastatic setting. Post-operative adjuvant therapy for previously resected NSCLC is allowed as long as the last dose was given greater than 1 year before study entry, and there is current evidence of disease progression.
  • No active malignancy other than NSCLC. Patients with a history of basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, or ductal or lobular carcinoma in situ of the breast within the past 3 years must have been treated with curative intent. Patients with a history of prior malignancy are eligible provided they were treated with curative intent and have been free of disease for > 3 years.

Comorbidities

For Cohort 1: (Bevacizumab eligible)

  • No history of gross hemoptysis (defined as bright red blood of a half-teaspoon or more) within 3 months prior to enrollment.
  • None of the following conditions within 6 months prior to enrollment: myocardial infarction, stroke or symptomatic peripheral vascular disease.
  • No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrollment.
  • No serious non-healing wound, ulcer or bone fracture.
  • Patients must not have unstable angina or NYHA classification of congestive heart failure of Grade ≥ 2.
  • No history of significant vascular disease (eg aortic aneurysm).
  • No current or recent (within 28 days of enrollment) full dose anticoagulants or thrombolytic agents.

For Cohort 2 (Bevacizumab ineligible):

  • None of the following conditions within 6 months prior to enrollment: myocardial infarction, stroke or symptomatic peripheral vascular disease.
  • Patients must not have unstable angina or NYHA classification of congestive heart failure of Grade ≥ 2.
  • No history of significant vascular disease (eg aortic aneurysm).

For ALL (Cohort 1 and Cohort 2):

  • Patients must not have psoriasis or porphyria.
  • No known hypersensitivity to 4-aminoquinoline compound.
  • Patients must not have known or suspected G-6P deficiency.
  • No know bleeding diathesis or coagulopathy.
  • No known GI pathology that would interfere with drug bioavailability.
  • No peripheral or sensory neuropathy > Grade 1 at study entry.
  • No known prior hypersensitivity to carboplatin, paclitaxel, bevacizumab or hydroxychloroquine or any of their components.
  • No ongoing or active infection at study entry.
  • Patients must not be receiving treatment for rheumatoid arthritis or systemic lupus erythematosus.
  • Patients must not have HIV or be taking HAART therapy.
  • Patients must not have a history of any condition (social or medical) that, in the opinion of the Investigator, might interfere with the patient's compliance with the protocol or pose additional or unacceptable risk to the patient.
  • Women must NOT be pregnant or breastfeeding.
  • Must not be taking hydroxychloroquine for treatment or prophylaxis of malaria.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01649947

Contacts
Contact: Clinical Trials Office 732-235-8675

Locations
United States, New Jersey
Robert Wood Johnson University Hospital at Hamilton Recruiting
Hamilton, New Jersey, United States, 08690
Contact: Biren Saraiya    609-586-7900      
Principal Investigator: Biren Saraiya         
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08901
Contact: Clinical Trials Office    732-235-8675      
Principal Investigator: Joseph Aisner, MD         
Sponsors and Collaborators
Rutgers, The State University of New Jersey
Rutgers Cancer Institute of New Jersey
Investigators
Principal Investigator: Joseph Aisner, MD Rutgers Cancer Institute of New Jersey
  More Information

No publications provided

Responsible Party: Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier: NCT01649947     History of Changes
Other Study ID Numbers: 031105, 0220110249, P30CA072720
Study First Received: July 20, 2012
Last Updated: May 15, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Rutgers, The State University of New Jersey:
Lung cancer
Non-small cell lung cancer
Advanced non-small cell lung cancer
Recurrent non-small cell lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Bevacizumab
Carboplatin
Hydroxychloroquine
Paclitaxel
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimalarials
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiparasitic Agents
Antiprotozoal Agents
Antirheumatic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 25, 2014